John Libbey Eurotext

Innovations & Thérapeutiques en Oncologie

MENU

ProTcell: A platform for cellular therapy to rearm the immune system against cancer and infections based on the power of the thymus Volume 8, issue 6, November-December 2022

Figures


  • Figure 1.

  • Figure 2

Tables


Authors
1 PhD, Head of clinical development Smart Immune Paris Biotech Santé 29, rue du faubourg St Jacques 75014 Paris France <aurelie.bauquet@smart-immune.com>
2 PhD, Chief Scientific Officer Smart Immune Paris Biotech Santé 29, rue du faubourg St Jacques 75014 Paris France <olivier.negre@smart-immune.com>
* Tirés à part : A. Bauquet
Remerciements et autres mentions :
Financement : aucun.
Liens d’intérêts : les auteurs sont salariés de Smart Immune.

Smart Immune is developing a platform for cellular therapies capable of rearming the immune system, enabling patients to fight cancer and infections. This platform, ProTcell, uses ex vivo cell culture technology to obtain T lymphoid progenitors in just seven days. These therapeutic cells from a donor have the capacity to repopulate and possibly regenerate the thymus, where they acquire a new polyclonal repertoire of T cell receptors within 100 days – instead of one to two years after regular blood (hematopoietic) stem cell transplantation. Currently being studied in Phase I/II trials in adult patients with high-risk hematological malignancies and in infants with severe combined immunodeficiencies, this thymus-based approach holds promise for accelerated immune reconstitution and improved clinical outcomes following allogeneic stem cell transplantation. Several complementary applications in immuno-oncology are being studied, such as the development of ProTcell cells armed with a CAR (chimeric antigen receptor). These allogeneic cell therapies are being considered in and outside the context of stem cell transplantation.